Dr. Judith Dalmau graduated in Biotechnology from the Autonomous University of Barcelona (UAB) in 2004 and obtained an MSc in Drug Design and Biomedical Sciences from Edinburgh Napier University in 2005.
In 2006 she launched a career in HIV research on joining Dr. Javier Martinez-Picado’s team at IrsiCaixa, obtaining her PhD in 2014. She has participated in several projects as a researcher and as a designer and coordinator of clinical cohorts and has also coordinated national and international projects. Her main line of research (the topic of her thesis) is the study of extreme phenotypes of HIV disease progression, including rapid progressors, viraemic non-progressors and exposed non-infected individuals. In June 2014 she joined the Research and Innovation Management Office (RIMO) at IrsiCaixa as project manager for the GREC and VIRIEVAC research groups. Her current professional position reflects research, cohort coordination and management roles.
Dr. Dalmau has published some 20 papers in high-impact journals, has participated in numerous international conferences and workshops and has been involved in several Spanish- and European-funded collaborative projects. She has been a lecturer on the MSc in AIDS Pathogenesis and Treatment since 2011 and also actively participates in many community outreach activities.
Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.
Highly pathogenic adapted HIV-1 strains limit host immunity and dictate rapid disease progression.
Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.
Copy number variation of KIR genes influences HIV-1 control.